PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila(Unknown), Matthew H. Taylor(Providence Portland Medical Center), Rodryg Ramlau(Poznan University of Medical Sciences), Jason E. Faris(Royal Marsden NHS Foundation Trust), Anna Wrona(Gdańsk Medical University), Marie Luise Hütter‐Krönke(University Hospital Ulm), Sebastian Szpakowski(Novartis (United States)), Geraldine Bostel(Novartis (Switzerland)), Hans Gelderblom(Leiden University Medical Center), Lori J. Wirth(Massachusetts General Hospital), Andreea Varga(Institut Gustave Roussy), Jean‐Pierre Delord, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Chia‐Chi Lin(National Taiwan University Hospital), Thomas Ernst(Jena University Hospital), Hongqian Wu, Peter M. Sadow(Massachusetts Eye and Ear Infirmary), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Angelica Fasolo, Armando Santoro(IRCCS Humanitas Research Hospital), Santiago Ponce Aix(Research Institute Hospital 12 de Octubre), Scott B. Cameron(Novartis (United States)), Dagmar Führer(West German Heart and Vascular Center Essen), Marcus O. Butler(University of Toronto)
Cited by 349
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k